Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. (GH) director Roberto Mignone reported the conversion of 264 restricted stock units into 264 common shares on October 21, 2026. After the transaction, he directly held 10,538 common shares and 6,336 restricted stock units. The award, granted November 8, 2024, vests over four years: 25% vested October 21, 2025, and the remaining 75% vests monthly over the three-year period thereafter.
Guardant Health, Inc. director Medina Manuel Hidalgo reported converting 232 restricted stock units into 232 common shares on October 17, 2026. The reported post-transaction positions were 4,873 restricted stock units and 5,252 common shares, both held directly. The award, granted July 17, 2024, vests over four years: 25% vested on July 17, 2025, and the remaining 75% vests monthly for the three-year period thereafter.
Guardant Health director Tariq Musa sold 116 shares of common stock on October 16, 2026, at $165.88 per share under a Rule 10b5-1 trading plan. On October 15, he acquired 250 common shares through conversion of 250 restricted stock units; 1,250 restricted stock units were reported following that transaction.
Guardant Health, Inc. director Tariq Musa gave notice of a proposed sale of 116 common shares through Charles Schwab & Co., Inc., with an aggregate market value of $19,242 and an approximate sale date of October 16, 2026. The shares were acquired through a restricted stock lapse on September 15, 2026. During the preceding three months, Musa reported three sales of 116 shares each, with gross proceeds of $18,941 on July 16, $18,148 on August 17, and $20,300 on September 16, 2026.
Guardant Health, Inc. (GH) director Alex M. Azar II sold 69 shares of common stock on October 14, 2026, at $159.89 per share. The transaction was identified as a sale in the open market or a private transaction and was made under a Rule 10b5-1 trading plan. Afterward, Azar reported directly holding 893 shares.
Guardant Health, Inc. director Alex M. Azar filed a notice covering the proposed sale of 69 common shares, with an aggregate market value of $11,032.00. The notice lists Charles Schwab & Co., Inc. as the broker and October 14, 2026, as the approximate date of sale. It also lists 69 shares acquired through a restricted stock lapse on October 12, 2026, and reports that Alex M. Azar II sold 826 shares during the prior three months on September 16, 2026, for gross proceeds of $144,550.00.
Guardant Health, Inc. director Alex M. Azar II reported converting 137 restricted stock units into 137 shares of common stock on October 12, 2026. After the transaction, he directly held 4,816 restricted stock units and 962 shares of common stock.
The award was granted September 12, 2025 and vests over four years: 25% vested September 12, 2026, and the remaining 75% vests monthly for the three-year period thereafter.
On October 1, 2026, Guardant Health, Inc. Chief Legal Officer John G. Saia converted four restricted stock unit awards into 7,063 shares of common stock. The company retained 3,706 shares to meet tax withholding obligations tied to the awards; the amount retained was not in excess of the tax liability. The reported price for the retained shares was $174.75 per share.
Guardant Health, Inc. (GH) Chief People Officer Terilyn J. Monroe reported conversion of 2,659 and 1,360 restricted stock units into the same respective numbers of common shares on October 1, 2026. On that date, 2,098 shares were retained by the company to meet tax withholding obligations tied to vesting, at $174.75 per share. The footnote states the amount retained was not in excess of the tax liability.
Guardant Health, Inc. Chief Information Officer Kumud Kalia exercised restricted stock units that converted into 6,046 shares of common stock on October 1, 2026. The company retained 3,067 shares for tax withholding, reported at $174.75 per share; the retained amount did not exceed the tax liability. No Rule 10b5-1 plan is reported.